PRESS-RELEASE ·Filed Jul 29, 2026
Press release · Earnings
VNDA drugs
VNDA drug pipeline →Price Chart
REPLAYWatch the reaction play outLoading chart...
How similar events traded
Executive Summary
Vanda Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 5, 2026.
Key Facts
- Vanda Pharmaceuticals Inc. announced it will report its Q2 2026 results on August 5, 2026.
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (10 analysts)
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302838270 |
Track record
8 reports on VNDA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.99 Now $3.81 −4.51% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.08 Now $3.81 −6.62% settles Nov 17
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $4.05 to $3.59 Now $3.81 −5.93% ▼ −11.36% −6.63% vs SPY
- Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $4.00 to $3.88 Now $3.81 −4.75% ▼ −3.00% −2.29% vs SPY
- Oct 21, 202626d ago Press Release Neutral 1/10 Entry $4.05 to $4.05 Now $3.81 −5.93% · 0.00% −0.71% vs SPY
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $4.54 to $4.09 Now $3.81 −16.08% ▼ −9.91% −8.42% vs SPY
- Jul 29, 202615w ago Press Release Neutral 1/10 Viewing Entry $5.18 Now $3.81 −26.45% No price data
- May 6, 202627w ago 8-K Mixed 6/10 Entry $6.39 to $6.43 Now $3.81 −40.38% ▲ +0.63% −0.88% vs SPY
Showing 8 of 8
US Market Status
Market Closed · Opens in 6h 34m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers